Sinclair IS Pharma PLC Receives Consensus Recommendation of “Buy” from Analysts (LON:SPH)
Shares of Sinclair IS Pharma PLC (LON:SPH) have received a consensus rating of “Buy” from the eight ratings firms that are currently covering the stock, Analyst Ratings Network.com reports. Two research analysts have rated the stock with a hold recommendation and six have given a buy recommendation to the company. The average twelve-month price target among brokerages that have issued ratings on the stock in the last year is GBX 36.50 ($0.60).
Several analysts have recently commented on the stock. Analysts at Jefferies Group cut their price target on shares of Sinclair IS Pharma PLC from GBX 50 ($0.83) to GBX 45 ($0.74) in a research note on Tuesday, July 29th. They now have a “buy” rating on the stock. Separately, analysts at Canaccord Genuity raised their price target on shares of Sinclair IS Pharma PLC from GBX 38 ($0.63) to GBX 44 ($0.73) in a research note on Tuesday, July 15th. They now have a “buy” rating on the stock. Finally, analysts at N+1 Singer reiterated a “buy” rating on shares of Sinclair IS Pharma PLC in a research note on Tuesday, July 15th. They now have a GBX 40 ($0.66) price target on the stock.
Shares of Sinclair IS Pharma PLC (LON:SPH) traded up 0.09% during mid-day trading on Monday, hitting GBX 29.15. 375,316 shares of the company’s stock traded hands. Sinclair IS Pharma PLC has a 52 week low of GBX 27.50 and a 52 week high of GBX 34.18. The stock’s 50-day moving average is GBX 30.1 and its 200-day moving average is GBX 30.61.
Sinclair IS Pharma plc is a specialty pharmaceutical company focused on treatments in dermatology, wound care, oncology support and critical care through surface technology and delivery systems.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.